EMA recommends expanded denosumab indication for myeloma

Amgen has announced that the European Medicine’s Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to expand the existing licence for denosumab (Xgeva®) to treat skeletal-related events in myeloma patients. This decision is based on the results from a Phase III trial which compared denosumab to zoledronic acid…

Details